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Sepsis and complement
Th  e complement system is a crucial part of the body’s 
defense mechanism against bacterial infection and is vital 
for protecting individuals against any disturbance of 
homeostasis associated with the appearance of foreign 
antigens [1]. Activation of the complement system can be 
initiated through the classic pathway antigen-antibody 
complexes or through the alternative and lectin pathways 
by non-immunologic molecules such as endotoxin 
(Figure 1). Th  e complement system orchestrates the 
immuno  logic network and links to elements of both 
innate and adaptive immunity and is an important 
inducer of an excessive inﬂ  ammatory host response and 
contributes to the clinical course, prognosis, and compli-
cations of sepsis [2,3]. Complement is activated early in 
sepsis (especially clinical sepsis) [4,5] and other condi-
tions involving inﬂ  ammation or immunologic alter a tions 
[6-8]. Bradykinin, complement factors, contact system 
components, estrogen, protease deﬁ  ciencies, and genetic 
polymorphisms are also implicated in certain types of 
non-allergic angioedema, including hereditary and drug-
induced [9].
C1-esterase inhibitor (C1 INH) is an alpha-globulin 
controlling the ﬁ   rst part of the classic complement 
pathway and is a natural inhibitor of complement and 
contact system proteases [10] and a major downregulator 
of inﬂ  ammatory processes in blood [11] (Table 1). C1 is 
the primary regulator of the plasma kallikrein-kinin 
system as evidenced by a lack of kallikrein inhibitory 
capability in plasma taken from patients with hereditary 
angioedema [12] and can also inactivate other proteases, 
including plasmin and tissue plasminogen activator, 
although the in vivo signiﬁ   cance remains unclear [8]. 
During sepsis, an overactive complement system may 
compromise the eﬀ  ectiveness of innate immunity [5,13].
Other activities of C1 include interactions with endo-
ge  nous proteins, with cells, and with infectious agents 
[8]. In addition to binding to endotoxin from Gram-
negative bacteria, C1 may bind to streptococcal lipo-
teichoic acid [14]. Th   ese may have potentially important 
functional consequences that are not dependent on 
protease inhibition.
Activation of the complement cascade can be triggered 
via the alternative complement pathway and the mannose-
binding lectin pathway. When these converge with the 
classic complement pathway (Figure 1), the C3-convertase 
is formed. Th  is cleaves C3 into C3a and the opsonizing 
C3b, which contributes to the formation of C5-con-
vertase [15]. C5-convertase subsequently cleaves C5 into 
the anaphylatoxin C5a and C5b, thereby initiating 
formation of the terminal membrane attack complex, 
consisting of C5b and C6-9 [15]. In sepsis, complement 
system activation is evidenced by the presence of the 
complement activation products C3a, C5a, and C5b-9 in 
plasma [6]. Th  ese anaphylatoxins have a spectrum of 
proinﬂ  ammatory activities [6]. In addition, there is a loss 
of C5a receptors (C5aRs) on blood polymorphonuclear 
neutrophils (PMNs) in patients with septic shock [6]. 
When C5a interacts with blood PMNs, signalling path-
ways are paralyzed. Th  is paralysis results in the loss of 
their innate immune function and likely contributes to 
the harmful consequences of sepsis [16]. Complement 
C5a has also been implicated in the pathogenesis of 
septic cardiac dysfunction [17].
Complement may interact with other systems in sepsis. 
Th   is has been comprehensively reviewed by Rittirsch and 
colleagues [7]. For example, it has been linked to the 
coagu  lation pathway which, when activated during sep  sis, 
may predispose to thrombosis and disseminated intra-
vascular coagulation [7]. Th  e resulting generation of 
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The purpose of this bench-to-bedside review is to 
summarize the literature relating to complement 
activation in sepsis and other critical illnesses and the 
role of C1-esterase inhibitor (C1 INH) as a potential 
therapy.
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© 2011 BioMed Central Ltdthrombin will aggravate the excessive inﬂ  ammatory 
response and further complement system activation and 
may be involved in the increased rate of apoptosis of 
lymphocytes and splenocytes, causing a marked decrease 
in cell numbers and resulting immunoparesis. Para  doxi-
cally, the apoptosis of macrophages and neutrophils 
seems to be unaﬀ  ected or even delayed. Complement 
may also interact with the autonomic nervous system, 
Figure 1. The classic and alternative pathways of the complement system. The squiggly line arrows indicate that proteolytic cleavage of the 
molecule at the tip of the arrow has occurred; a line over a complex indicates that it is enzymatically active. Note that the nomenclature of the 
cleavage products of C2 is undecided. Some call the large fragment C2a and others call it C2b. Here, all small fragments are labeled ‘a’ and all large 
fragments are labeled ‘b’. Hence, the C3 convertase is depicted as C4b,2b. Note that proteases associated with the mannose-binding lectin cleave 
C4 as well as C2. Reprinted with permission from McGraw-Hill Medical [67].
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investigations are needed to establish the signiﬁ  cance of 
these various interactions and the identiﬁ  cation of new 
therapeutic targets.
C1 inhibitor
As stated above, the biological activities of C1 INH include 
the inactivation of a variety of proteases, includ  ing comple-
ment system proteases (C1r, C1s, and MASP2), contact 
system proteases (factor XII, plasma, and kalli  krein), 
intrinsic coagulation proteases (factor XI), and ﬁ  brino  lytic 
proteases (plasmin and tissue plasminogen activator) 
(Table 1) [8]. In addition to inhibiting proteases, C1 INH 
interacts with extracellular matrix components, the 
comple  ment component C3, endothelial cells and 
leukocytes, and endotoxin.
C1 INH is licensed in Europe and the US for the 
management of hereditary angioedema (including acute 
attacks and routine prophylaxis). In addition, over the past 
20 years    , administration of C1 INH has been associated 
with improved survival or correction (or both) of bio-
chemical parameters in a variety of clinical scenarios. 
However, these have been predominantly lab-based 
studies; human investigations have been mainly at the level 
of individual anecdote, small case series, or small 
randomized controlled trials. Table 2 summarizes the 
research and clinical studies included in the present review.
Animal models
Sepsis and endotoxic shock
C1 INH improves outcomes in animal models of sepsis. 
Croner and colleagues [18] reported a reduction in 
hepatic leukocyte-endothelial interactions in post-sinu-
soidal venules and an improved hepatic perfusion in 
lipopolysaccharide-induced sepsis in rats. Decreased 
leukocyte adherence and suppression of the increase in 
vascular permeability were also demon  strated in both 
rats and mice treated with C1 INH [19,20]. Fischer and 
colleagues [21]  reported improved survival in C3-deﬁ  -
cient mice challenged with endotoxin and also demon-
strated the role of complement in endotoxin clearance. In 
a rabbit model, combined anti-thrombin and C1 INH 
treatment during early endotoxic shock decreased organ 
ﬁ  brin deposition and improved cardiovascular stability 
[22]. Treatment with C1 INH also prevented the hypox-
emia induced by endotoxic shock in dogs [23] and 
decreased cytokine production in both primates [24] and 
mice [25].
In a cecal ligation and puncture (CLP) models of sepsis, 
treatment with a single dose of C1 INH improved 
survival [26]. Th  is improvement was enhanced by the 
administration of multiple doses. However, survival was 
not improved with a single dose at 6 hours rather than 
immediately after puncture but was improved when two 
doses were given at 3 and 9 hours after CLP. Th  is  ﬁ  nding 
led to the suggestion that the eﬀ  ectiveness of C1 INH 
treatment in sepsis may relate, at least in part, to its 
ability to enhance phagocytosis rather than inhibit the 
complement and contact systems.
Ischemia-reperfusion injury and acute pancreatitis
Animal studies have shown that administration of C1 
INH at or just prior to reperfusion results in a reduction 
in myocardial injury; reduced plasma levels of creatine 
Table 1. Activities of C1 inhibitor 
Protease inhibition 
  Complement system  C1r, C1s, MASP2
  Plasma kallikrein-kinin system  Plasma kallikrein, factor XII
  Fibrinolytic system  Plasmin, tissue plasminogen activator
  Coagulation system  Factor XI, thrombin
Interactions with endogenous proteins 
 Complement  system  C3b
  Extracellular matrix  Type IV collagen, laminin, entactin, fi  brin
Interactions with cells 
  Circulating cells  Neutrophils, macrophages
  Vascular cells  Endothelial cells (E and P selectins)
Interactions with infectious agents 
 Endotoxin  Escherichia coli 011:B4, E. Coli 0127:B5, E. Coli 055:B5, E. Coli K-235, Salmonella typhimurium, Salmonella 
   minnesota, Salmonella typhosa
 Bacteria  Bordetella pertussis, E. coli, Serratia marcescens
 Parasites  Plasmodium falciparum
Reprinted with permission from Elsevier [8].
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Type of    Model/Study     
study Indication  type    Objective  Findings  Reference
Laboratory  Sepsis  Rat   Infl  uence of C1 INH on microcirculation   Leukocyte sticking to the endothelial wall in  [18]
      and leukocyte-endothelial interaction   post-sinusoidal venules was reduced in C1 INH rats. 
      in the liver  Hepatic microcirculatory disturbances may be 
        reduced by C1 INH.
   Baboon  Eff  ect of C1 INH on physiologic and   C1 INH did not prevent the hemodynamic/  [24]
      infl  ammatory response  hematologic changes. Activation of fi  brinolysis and 
        development of intravascular coagulation were 
       unaff  ected. C1 INH reduced decreases in plasma levels 
        of factor XII and prekallikrein and abrogated the systemic 
        appearance of C4b/c and reduced elaboration of 
       various  cytokines.
   Mouse  Eff  ect on survival  C1 INH blocked LPS-binding protein-dependent   [25]
        binding and suppressed LPS-induced TNF-α mRNA 
       expression.
   Mouse  Eff  ect on survival   C1 INH enhanced the bactericidal activity of blood   [26]
        neutrophils and peritoneal exudate leukocytes. 
        Survival increased with C1 INH.
 Experimental    Rat Eff  ects of C1 INH on arterial  Decrease in arterial oxygenation was attenuated by  [19]
  endotoxemia    oxygenation and tissue oxygenation   pre-treatment with C1 INH. Tissue oxygenation 
      of jejunal mucosa during endotoxemia  decreased in LPS and C1 INH groups without 
       signifi   cant  diff  erence after 120 minutes of endotoxemia. 
        Endotoxin-induced tissue hypoxia of the intestinal 
        mucosa was not prevented by C1 INH. 
   Rat    Eff  ects of C1 INH on intestinal   C1 INH reduced endotoxemia (9.5%) and attenuated  [20]
      functional capillary density, leukocyte   intestinal leukocyte adherence in submucosal
      adherence, and mesenteric plasma   venules (35%) and mesenteric plasma extravasation
      extravasation  (44%). C1 INH diminished changes in the intestinal 
       microcirculation. 
    Mouse   Investigate the role of complement in   C3- and C4-defi  cient mice were signifi  cantly more  [21]
      endotoxic shock  sensitive to endotoxin. C1 INH had a protective 
       eff  ect against endotoxin.
   Rabbit  Eff  ect of antithrombin III + C1 INH on   Combined treatment was associated with decreased  [22]
      intravascular organ fi  brin deposition   clot formation in lungs and livers. There was no clear
      and cardiorespiratory changes  dose-dependent eff  ect.
   Dog  Eff  ect on cardiovascular and   C1 INH prevented hypoxemia.  [23]
     respiratory  dysfunction
 Ischemia-  Cat Cardioprotective  eff  ect  C1 INH improved recovery of cardiac contractility  [27]
  reperfusion       and preservation of coronary vascular endothelial
 injury     function.
   Rat Cardioprotective  eff  ect  C1 INH attenuated myocardial injury and neutrophil   [28]
        infi  ltration even after 48 hours of reperfusion.
   Rat Eff  ect on C3 activity in ischemic   C1 INH suppressed C3 mRNA expression and protein  [32]
      myocardial tissue  synthesis and prevented myocardial cell injury.
    Rat  Protection against myocardial   C1 INH improved cardiac function and hemodynamics  [31]
      cell injury   and reduced myocardial infarct size.
    Mouse  Role and mechanism of C1 INH in   C1 INH reduced intestinal tissue injury and attenuated  [33]
      alleviating intestinal injury  leukocyte infi  ltration and improved survival.
  Acute   Mouse/Rat  Evaluate the eff  ect of C1 INH  C1 INH slightly ameliorated the degree of histological  [35]
  pancreatitis      alterations, but increase in serum amylase was reduced 
        in diet-induced pancreatitis only. C1 INH did not improve 
        survival in taurocholate- and diet-induced pancreatitis.
  Xenotrans-  Pig  Inhibition of complement-mediated  C1 INH inhibited C1 activation.   [38]
  plantation    cytotoxicity and activation of 
     endothelial  cells
   Pig Eff  ect on hyperacute rejection  Survival improved. C1 INH inhibited complement   [39]
        activation, and no contact activation was found. 
        Leukocytes and platelet activation were reduced 
        by C1 INH. 
Continued
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endothelial expression of P-selectin and ICAM-1 (inter-
cellular adhesion molecule-1) [27-30]. C1 INH also sup-
pressed ischemia-reperfusion-induced apoptosis in rat 
myocardial cells with a possible eﬀ  ect on myocardial C3 
expression [31,32].
Beneﬁ  cial eﬀ  ects of C1 INH have also been described 
in a number of other animal ischemia-reperfusion 
models, including skeletal muscle, liver, cerebral artery, 
and mesenteric artery occlusion. Th  ese studies were 
reviewed in detail by Davis and colleagues [8]. More 
recently, C1 INH treatment reduced intestinal tissue 
injury, attenuated leukocyte inﬁ   ltration, and improved 
survival in a murine model of intestinal ischemia-reper-
fusion injury [33]. Th  e authors proposed that C1 INH 
may play a direct role in the suppression of leukocyte 
transmigration into reperfused tissue.
Complement and kinin pathways are also activated in 
acute pancreatitis [34]. C1 INH treatment ameliorated 
the degree of histological alterations in animal models of 
Table 2. Continued
Type of    Model/Study     
study Indication  type    Objective  Findings  Reference
Laboratory Xenotrans-  Pig  Eff  ect on hyperacute rejection  C1 INH attenuated hyperacute rejection by   [41]
  plantation      decreasing the activation of adhesion molecules.
   Pig Eff  ect on hyperacute rejection   C1 INH at 10 U/mL prolonged survival time and   [42]
        diminished complement activation but did not 
        prevent rapid lung injury.
   Pig Eff  ect on hyperacute rejection   C1 INH improved pulmonary function but not survival.  [40]
   Pig/Monkey  Eff  ect on hyperacute rejection  C1 INH therapy with standard immunosuppressive   [43,44]
        regimen prevented rejection but did not improve 
       survival. 
 Thermal  injury  Pig Eff  ect on capillary leak syndrome and   C1 INH reduced complement activation and improved  [45]
      infl  ammatory tissue destruction  clinical outcome.
 Meningitis  Mouse/Rat  Eff  ect on clinical illness, bacterial   C1 INH increased bacterial clearance.  [47]
      clearance, and infl  ammatory response
Clinical  Sepsis  Case series   Eff  ect on functional levels on C1 INH  C1 INH may attenuate complement and contact   [49,50]
       activation.
   Double-blind    Effi   cacy and safety of C1 INH  C1 INH increased plasma C1 INH antigen and activity  [51]
    RCT    levels during days 1 to 4 and lowered serum creatinine 
        concentrations on days 3 and 4. Organ failure was less 
        pronounced. Mortality was unaff  ected.
   Case  series  Eff  ect on neutrophil activation  Elastase-alpha(1)-antitrypsin complex and lactoferrin   [52]
        levels were reduced.
   Open-label  Effi   cacy and safety of C1 INH  Complement activity was inhibited, and survival was   [53]
       improved. 
    Comparative  To measure functional C1 INH levels in   There was no diff  erence in functional C1 INH levels  [54]
      newborns with culture-proven sepsis  between treatment group and controls.
  Ischemia-  Case series  C1 INH as rescue therapy  C1 INH restored myocardial function.  [55]
 reperfusion 
 injury
   Open-label  Eff  ect of C1 INH following reperfusion  48-hour infusion of C1 INH was safe and inhibited   [56]
       complement  activation.
   Randomized,    Eff  ects of C1 INH in ST segment  Arterial pressure, cardiac index, and stroke volume  [58]
    double-bind  elevation myocardial infarction  were improved in the C1 INH group. No adverse 
       eff  ects were observed.
  Emergency   Comparative,   Eff  ect of C1 INH on complement  Complement activity was reduced. There was no eff  ect  [57]
  CABG  open-label  activation, myocardial cell injury, and   on mortality. 
     clinical  outcome 
 Transplantation  Comparative,    Effi   cacy  In C1 INH patients, plasma levels of C5a and C4d and  [59]
    open-label     fl  uid levels were normalized.
    Case studies  -  In case 1, pleural eff  usions were reduced within   [60]
        12 hours, leading to normal graft function within 
        4 days. In case 2, pleural eff  usions were reduced from 
        19 L per day to 300 mL within 3 days of treatment. 
C1 INH, C1-esterase inhibitor; CABG, coronary artery bypass grafting; LPS, lipopolysaccharide; RCT, randomized controlled trial; TNF-α, tumor necrosis factor-alpha.
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Murine models demonstrate that C5a exerts an anti-
inﬂ  ammatory  eﬀ   ect in pancreatitis [36], but, to date, 
there is only limited evidence for the use of C1 INH in 
acute pancreatitis [35].
Transplantation
Antibody-mediated complement activation is implicated 
in transplant rejection [8,37]. C1 INH inhibited the 
action of porcine aortic cells incubated with human 
serum [38] and improved perfusion and survival of pig 
kidneys [39]. C1 INH has also been reported to provide 
some protection against injury in ex vivo mouse lung or 
pig lung whole human blood models [40-42]. C1 INH has 
also suppressed hyperacute and acute vascular rejection 
in porcine models [43,44].
Thermal injury
Th   ermal injury is associated with profound immunologic 
alterations and activation of the complement system [45]. 
Th  is association may play an important role in the 
development of capillary leak syndrome and inﬂ  am  ma-
tory tissue destruction. In a porcine model, C1 INH 
treatment reduced complement activation by 50% and 
reduced edema formation [45]. Th  ese data suggest that 
C1 INH therapy may have a potential therapeutic role in 
the management of burn injury.
Pneumococcal meningitis
Complement-mediated opsonic activity may appear in 
the cerebrospinal ﬂ   uid of patients who recover com-
pletely from bacterial meningitis and may inﬂ  uence the 
outcome of the disease [46]. In a rat model of meningitis, 
treatment with C1 INH was associated with reduced 
clinical severity, a less pronounced inﬂ  ammatory inﬁ  l-
trate around the meninges, and lower brain levels of pro-
inﬂ  ammatory cytokines and chemokines. C1 INH treat-
ment also increased bacterial clearance, possibly through 
an upregulation of CR3 [47]. Th   ese data suggest that C1 
INH may be a useful agent in the treatment of pneumo-
coccal meningitis. However, further clinical studies are 
needed in light of data from clinical studies of the 
monoclonal antibody eculizumab (that binds with high 
aﬃ     nity to the complement protein C5) suggesting an 
increased risk of sepsis necessitating meningococcal 
vaccination 2 weeks prior to treatment [48].
Clinical studies
Sepsis and endotoxic shock
Th   ere are limited clinical data on the use of C1 INH in 
human sepsis. Early studies in small numbers of patients 
with septic shock reported that C1 INH treatment 
suppressed activation of the complement and contact 
systems [49,50]. Th  ese investigators then performed a 
double-blind study in 40 patients with severe sepsis or 
septic shock [51]. C1 INH was infused intravenously over 
the course of an hour, starting with 6,000 IU, followed by 
3,000, 2,000, and 1,000 IU at 12-hour intervals. Patients 
treated with C1 INH had less severe multiple organ 
dysfunction and improved renal function, but there was 
no diﬀ   erence in mortality compared with the control 
group. Th  e same group also reported that C1 INH 
reduced circulating elastase-α1-antitrypsin complex levels 
as well as complement activation and interleukin-8 
release [52]. As neutrophils may contribute to the 
development of organ dysfunction during sepsis, the 
reduction in neutrophil count after C1 INH treatment 
may account in part for its favorable eﬀ  ect. A positive 
eﬀ  ect on mortality and an inhibitory eﬀ  ect of C1 INH 
(dose of 12,000 IU) on complement was also reported in 
an open-label Russian study of patients with sepsis [53].
In a recently published study, Tapisiz and colleagues 
[54] measured levels of C1 INH in 18 newborns who had 
had neonatal sepsis and who were blood culture-positive. 
Th   ese levels were repeated 48 hours later and compared 
against 23 healthy controls of the same gestational age. 
Th  e authors reported no diﬀ   erence between the two 
groups and no diﬀ   erence in edema formation and 
concluded that, in neonates, other factors are responsible 
for vascular leak and edema [54].
Ischemia-reperfusion injury
Bauernschmitt and colleagues [55] reported on the use of 
C1 INH as salvage therapy in three patients following 
emergency surgical revascularization after failed percu-
taneous transluminal coronary angioplasty. Initially, a 
2,000-unit bolus of C1 INH was administered, followed 
by 1,000 units at 12 and 24 hours after surgery. Th  e 
authors reported rapid hemodynamic stabilization of all 
three patients. C1 INH therapy instituted after thrombo-
lytic therapy was reported by de Zwaan and colleagues 
[56] to diminish complement activation and reduce 
troponin T and creatine kinase levels in patients with 
myocardial infarction by 36% and 57%, respectively 
(P  =  0.001). In a double-blind study of 57 patients 
undergoing emergency coronary artery bypass surgery, 
Th   ielmann and colleagues [57] also reported a reduction 
in cardiac troponin levels in the subgroup of patients 
treated with C1 INH before 6 hours.
Th   e cardioprotective eﬀ  ects of C1 INH in ST segment 
elevation myocardial infarction in 80 patients undergoing 
emergent reperfusion with coronary artery bypass 
grafting were investigated in an Italian double-blind 
study [58]. Th  e authors reported statistically signiﬁ  cant 
diﬀ   erences between the C1 INH-treated patients and 
controls for cardiopulmonary bypass support (P = 0.04), 
administration of high-dose inotropes (P = 0.001), time 
to intubation (P = 0.03), and intensive care and hospital 
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volume (P = 0.03) and cardiac index (P = 0.02) were also 
signiﬁ  cantly improved in the C1 INH group.
Transplantation
Nurnberger and colleagues [59] reported on the use of 
C1 INH in 15 patients with severe capillary leakage 
syndrome. Cumulative dosage was 180 units/kg body 
weight (initial dose: 60 units/kg followed by two doses at 
30 units/kg and four doses at 15 units/kg every 12 hours). 
One year after bone marrow transplantation, the survival 
rates were 57% in the C1 INH treatment group and 14% 
in the control group (7 patients not treated with C1 INH) 
(P = 0.008). After infusion of C1 INH, the plasma levels 
of C5a and C4d normalized and the activity of C1 INH 
rose to 139% ± 10% of normal human plasma (NHP) pool 
(mean ± standard deviation).
Strüber and colleagues [60] reported the use of high-
dose C1 INH given over 2 days in two patients with graft 
failure either due to reperfusion injury immediately after 
transplantation or due to an acute rejection 2 months 
after double-lung transplantation. In both cases of graft 
failure, a capillary leak syndrome occurred with pleural 
eﬀ  usions of from 7 L per day to more than 10 L per day. 
In one case, the disturbance of gas exchange during 
severe reperfusion injury could not be treated eﬀ  ectively 
with other treatment modalities such as nitric oxide 
ventilation or surfactant administration. With the use of 
C1 INH, pleural eﬀ  usions decreased within 12 hours, 
leading to normal graft function within 4 days. In the 
second recipient, acute rejection forced the use of 
extracorporeal membrane oxygenation (ECMO) within 
24 hours despite immunosuppressive therapy. After 
administration of C1 INH, pleural eﬀ  usions  decreased 
from 19 L per day to 300 mL within 3 days of treatment. 
ECMO was discontinued after C1 INH treatment and the 
patient was extubated 2 weeks later [60].
Thermal injury
Kowal-Vern and colleagues [61]  reported signiﬁ  cant 
decreases in C1 INH levels (P = 0.0001) in 60 patients 
with thermal injuries and sepsis on the ﬁ   rst day of 
admission, although this had increased to near-normal 
levels by day 5.
Conclusions
C1 INH is a multifaceted anti-inﬂ  ammatory protein that 
exerts its eﬀ  ects through a variety of mechanisms that 
may or may not depend on protease inhibition via 
covalent bonding [62] or other non-covalent interactions 
with proteins, cell surfaces, or lipids. C1 INH binds to a 
variety of extracellular matrix components, including 
type IV collagen, laminin, entactin, and ﬁ  brinogen.  A 
non-covalent interaction with C3b inhibits formation of 
the alternative pathway C3 convertase, whereas an 
interaction with E and P selectins on endothelial cells is 
mediated by the Lewis(x) tetrasaccharides expressed on 
C1 INH. Th  ese interactions result in suppression of 
leukocyte rolling and transmigration. A fourth inter-
action is the binding of C1 INH to Gram-negative 
bacterial endotoxin and this results in suppression of 
endotoxic shock by interfering with the interaction of 
endotoxin with its receptor complex on macrophages. 
Lastly, C1 INH binds directly to Gram-negative bacteria, 
leading to suppression of the development of sepsis, as 
demonstrated in the CLP model. It has been suggested 
that pharmacological inhibition of C5a or C5aR may be 
protective in sepsis [63].
As discussed above,  C1 INHs are currently licensed for 
routine prophylaxis and treatment of angioedema attacks 
in adolescents and adults. C1 INHs have also been used for 
the treatment of RAAS (renin-angiotensin-aldosterone 
system) blocker-induced angioedema and acquired angio-
edema. Other therapeutic options for bradykinin-medi-
ated angioedema include inhaled epi  nephrine, cortico-
steroids, bradykinin receptor antago  nists (icatibant), and 
the plasma kallikrein inhibitor ecallantide [9,64,65]. C1 
INHs have been shown to be beneﬁ  cial not only in sepsis 
and Gram-negative endo  toxic shock but also in vascular 
leak syndrome, transplant rejection ischemia-reperfusion 
injury, intestinal ischemia and reperfusion, pancreatitis, 
and burns. However, serious thrombogenesis has been 
reported following high-dose use of human C1 INH in 
neonatal patients undergoing cardiac surgery using an 
extracorporeal circu  lation [64]. C1 INHs may also have a 
role in the treatment of cerebral malaria [66]. Clinical 
studies and well-designed dose-titrating studies are 
needed to clarify the levels of C1 INH needed to produce 
a therapeutic eﬀ  ect and to establish whether treatment 
with C1 INH has a place in the management of these 
conditions. Other infections in which the inﬂ  am  matory 
response contri  butes to mortality, such as pneumonia 
and peritonitis, may also be worthy of examination.
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